Intravesical Therapy of Superficial Urothelial Bladder Cancer with BCG and Epirubicin 50 Mg - Comparative Analysis
By:
Abstract
Bladder cancer is a heterogeneous disease in molecular, histological and clinical aspects. Treatment should also be considered from different angles - surgery, intravesical chemo- or immunotherapy, radiation therapy and lifestyle changes. Intravesical treatment of superficial bladder cancer with Еpirubicin or Bacillus Calmette-Guérin (BCG) is a continuation of surgical treatment to reduce or eliminate further recurrence.
DOI: https://doi.org/10.2478/jbcr-2022-0009 | Journal eISSN: 1313-9053
Language: English
Page range: 70 - 73
Submitted on: Jan 18, 2022
Accepted on: May 11, 2022
Published on: Jul 13, 2022
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Related subjects:
© 2022 Nikolay I. Nikolov, Vladislav R. Dunev, Angel A. Anatoliev, Nikolay H. Kolev, Martin B. Stoykov, Boyan S. Atanasov, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.